Cornelis A. J. De Jong

Cornelis A. J. De Jong

Auto-generated profile, based on publicly available information

Cornelis A. J. De Jong

Behavioral Science Institute, Radboud University Nijmegen, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2019 in Drug and Alcohol Review
Verified
Journal Article
Open access
PDF file
CBCarolien Bruijnen
Carolien Bruijnen
BDBoukje Dijkstra
Boukje Dijkstra
SWSerge J. W. Walvoort
Serge J. W. Walvoort
Wiebren MarkusWiebren Markus
Wiebren Markus
JVJoanne VanDerNagel
Joanne VanDerNagel
CJCornelis A. J. DE Jong
Cornelis A. J. DE Jong
Introduction and Aims: Cognitive impairments in substance use disorder predict treatment outcome and are assumed to differ between substances. They often go undetected, thus the current study focuses on the prevalence of and differences in cognitive functioning across substances by means of a cognitive screen at the early stage of addiction treatment.Design and Methods: The Montreal Cognitive Assessment was administered to outpatients seeking treatment for substance use disorder. Patient characteristics (age, years of regular use, polysubstance use, severity of dependence/abuse, depression, anxiety and stress) were also taken into account.Results: A total of 656 patients were included (n = 391 used alcohol, n = 123 used cannabis, n = 100 used stimulants and n = 26 used opioids). The prevalence of cognitive impairments was 31%. Patients using alcohol had a lower total‐ and memory domain score than those using cannabis. Patients using opioids scored lower on visuospatial abilities than those using cannabis or stimulants. Younger patients scored higher than older patients. No effect was found for the other investigated characteristics.Discussion and Conclusions: Given the high prevalence of cognitive impairments, standard screening at an early stage of treatment is important to determine the course of treatment and maximise treatment outcome. Caution is needed in interpreting results about opioids due to an underrepresentation of this patient group, and more research is needed on the effect of age on Montreal Cognitive Assessment performance.

9 April 2020 in International Journal of Psychiatry in Clinical Practice
Verified
Journal Article
Open access
CBCarolien Bruijnen
Carolien Bruijnen
BDBoukje Dijkstra
Boukje Dijkstra
SWSerge J. W. Walvoort
Serge J. W. Walvoort
MBManon J. J. Budy
Manon J. J. Budy
HBHarmen Beurmanjer
Harmen Beurmanjer
Roy P. C. KesselsRoy P. C. Kessels
Roy P. C. Kessels
Objectives: The Montreal Cognitive Assessment (MoCA) is a cognitive screen, available in three alternate versions. Aims of the current study were to examine the effects of age, education and intelligence on MoCA performance and to determine the alternate-form equivalence and test–retest reliability of the MoCA, in a group of healthy participants. Method: In 210 participants, two MoCA versions and an estimator for premorbid intelligence were administered at two time points. Results: Age, education and estimated premorbid intelligence correlated significantly with the total score (MoCA-TS) and the Memory Index Score (MoCA-MIS). Systematic differences between MoCA version 7.1 and alternate versions 7.2 and 7.3 were only found for the items animal naming, abstract reasoning and sentence repetition. Test–retest reliability of the MoCA-TS was good between 7.1 and 7.2 (ICC: 0.64) and excellent between 7.1 and 7.3 (ICC: 0.82). For the MoCA-MIS, coefficients were poor (ICC: 0.32) to fair (ICC: 0.48), respectively. Conclusion: Adequate norms are needed that take the effects of age, education and intelligence on MoCA performance into account. All three MoCA versions are largely equivalent based on MoCA-TS and the test–retest reliabilities show that this score is suitable to monitor cognitive change over time. Comparisons of the domain-specific scores should be interpreted with caution.

19 August 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MHMarline G. Harmsen
Marline G. Harmsen
MJMarieke Arts-De Jong
Marieke Arts-De Jong
NHNicoline Hoogerbrugge
Nicoline Hoogerbrugge
AMAngela H. E. M. Maas
Angela H. E. M. Maas
JPJudith B. Prins
Judith B. Prins
JHJoanne A. de Hullu
Joanne A. de Hullu
Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is currently recommended to BRCA1/2 mutation carriers. This procedure decreases the elevated ovarian cancer risk by 80–96 % but it initiates premature menopause as well. The latter is associated with short-term and long-term morbidity, potentially affecting quality of life (QoL). Based on recent insights into the Fallopian tube as possible site of origin of serous ovarian carcinomas, an alternative preventive strategy has been put forward: early risk-reducing salpingectomy (RRS) and delayed oophorectomy (RRO). However, efficacy and safety of this alternative strategy have to be investigated. A multicentre non-randomised trial in 11 Dutch centres for hereditary cancer will be conducted. Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing without (a history of) ovarian carcinoma. Participants choose between standard RRSO at age 35–40 (BRCA1) or 40–45 (BRCA2) and the alternative strategy (RRS upon completion of childbearing and RRO at age 40–45 (BRCA1) or 45–50 (BRCA2)). Women who opt for RRS but do not want to postpone RRO beyond the currently recommended age are included as well. Primary outcome measure is menopause-related QoL. Secondary outcome measures are ovarian/breast cancer incidence, surgery-related morbidity, histopathology, cardiovascular risk factors and diseases, and cost-effectiveness. Mixed model data analysis will be performed. The exact role of the Fallopian tube in ovarian carcinogenesis is still unclear. It is not expected that further fundamental research will elucidate this role in the near future. Therefore, this clinical trial is essential to investigate RRS with delayed RRO as alternative risk-reducing strategy in order to improve QoL. ClinicalTrials.gov ( NCT02321228 )

21 December 2015 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
JGJeanny J.A. de Groot
Jeanny J.A. de Groot
SAStephanie M.C. Ament
Stephanie M.C. Ament
JMJosé M.C. Maessen
José M.C. Maessen
CDCornelis H.C. Dejong
Cornelis H.C. Dejong
JKJos M.P. Kleijnen
Jos M.P. Kleijnen
BSBrigitte F.M. Slangen
Brigitte F.M. Slangen

1 July 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
MJMarieke Arts-De Jong
Marieke Arts-De Jong
GBGeertruida H. de Bock
Geertruida H. de Bock
CAChristi J. van Asperen
Christi J. van Asperen
MMMarian J.E. Mourits
Marian J.E. Mourits
JHJoanne A. de Hullu
Joanne A. de Hullu
CKC. Marleen Kets
C. Marleen Kets

18 June 2015 in Journal of Medical Internet Research
Verified
Journal Article
Open access
EHElke D ter Huurne
Elke D ter Huurne
HHHein Arnoud de Haan
Hein Arnoud de Haan
MPMarloes G Postel
Marloes G Postel
JPJob van der Palen
Job van der Palen
JVJoanne VanDerNagel
Joanne VanDerNagel
CDCornelis AJ DeJong
Cornelis AJ DeJong
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet